Precigen Q3 2021 Earnings Report

50% objective response rate in relapsed or refractory acute myeloid leukemia patients treated with PRGN-3006.

40% objective response rate and 60% disease control rate in recurrent or metastatic human papilloma virus-associated cancer patients treated in the PRGN-2009 combination arm.

Preliminary PRGN-2012 Phase 1 data show encouraging clinical activity, including ongoing reduction/elimination of the need for surgical intervention.

PRGN-3005 and PRGN-3006 UltraCAR-T demonstrate favorable safety profiles with no dose-limiting toxicities or neurotoxicity, dose-dependent in vivo expansion and durable persistence.